期刊文献+

难治性急性髓性白血病治疗进展

Advances in studies on the therapy of refractory acute myelogenous leukemia
下载PDF
导出
摘要 难治性急性髓性白血病的治疗,仍是当今临床血液学一个难以突破的棘手问题,国内外多种治疗效果均不满意。本文就新型化疗药的应用、传统药物的新用、靶向治疗、造血干细胞移植等方面内容作一综述。 The therapy in refractory acute myelogenous leukemia is still one of unbreakthroughable problems in clinic hematology at present. The efficacies of many sorts of therapeutic mathods are dissatisfactory aroud the wortd. As to the use of neotype chemotherapeutic agents, the new use of orthodox drugs, targeted therapy, hematopoietic stem cell transplantation, etc, the article does a reivew.
出处 《国际内科学杂志》 CAS 2007年第1期29-33,共5页 International Journal of Internal Medicine
关键词 难治性急性髓性白血病 联合化疗 靶向治疗 造血干细胞移植 Refactory acute myelogenous leukemia Combined chemotherapy Targeted therapy Hematopoietic stem cell transplantation
  • 相关文献

参考文献28

  • 1Cortes J, Estey E, Beran M, et al. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed leukemia. Leuk Lymphoam, 2000,36 (56) :479-484.
  • 2Giles FJ, Cortes JE, Kantarjian HM, et al. A fludarabine,topotcan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res, 2004,28(4) :353-357.
  • 3Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine,and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol, 2001,68(4) :237-245.
  • 4Rubia J, Regadera A, Martin G, et al. FLAG-IDA regimen(fludarabine, cytarabine, idarubicin and G-CSF ) in the treatment of patients with high-risk myeloid malignancies.Leuk Res, 2002,26 ( 8 ) :725-730.
  • 5Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33^+ primary resistant or relapsed acute myeloid leukmeia. Leuk Res, 2003, 27(10) :893-897.
  • 6Apostolidou E, Estey E, Cortes J, et al. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res, 2005,27 (4) :301-304.
  • 7Bass AJ, Gockerman JP, Hammett E, et al. Phase Ⅰ evaluation of prologed infusion gemcitabine with irinottecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol,2002,20( 13 ) :2995-3000.
  • 8Rizzieri DA, Ibom VK, Moore JO, et al. Phase Ⅰ evaluation of prologed infusion gemcitabine with fludarabine for relapsed or refractory acuted myelogenous leukemia. Clin Cancer Res, 2003,9(2) :663-668.
  • 9Niitsu N, Hayashi Y, Sugita K, et al. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and lalpha, 25-dihydroxyvitamin D3. Br J Haematol, 2001,112(2) :315-326.
  • 10Polkowski K, Skicrski JS, Mazurek AP, et al. Anticancer activity of genistein-piperazine complex. In vitro study with HL-60 cells. Acta Poloniac Pharmaceutia, 2000,57 ( 3 ) :223 -232.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部